Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) are exquisitely sensitive to imatinib. Almost all patients achieve a complete molecular remission (CMR) by nested reverse transcription polymerase chain reaction, which can be maintained with low-dose imatinib (eg, 3 × 100...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Metzgeroth, Georgia, Schwaab, Juliana, Naumann, Nicole, Jawhar, Mohamad, Haferlach, Torsten, Fabarius, Alice, Hochhaus, Andreas, Hofmann, Wolf-Karsten, Cross, Nicholas C. P., Reiter, Andreas
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2020
Pynciau:
Stimulus Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013256/
https://ncbi.nlm.nih.gov/pubmed/31995156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001111
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg